Better than Antibodies?
Plumbing RNAi's Potential: Medicines Co., Alnylam Join Up
By Randy Osborne
Staff Writer
Staff Writer
The Medicines Co. likes Alnylam Pharmaceuticals Inc.'s RNA interference (RNAi) approach to blocking proprotein convertase subtilisin/kexin type 9 (PCSK9) enough to pay $25 million up front plus as much as $180 million in milestone payments, but how the method might stand up against late-stage antibodies remains to be seen clinically.